Buyout Desk
Exit

Trustar sells 15.4% stake in TAUNS Laboratories to Kurabo Industries

Trustar Capital Japan Fund III agreed to transfer 16.4 million TAUNS shares, 15.4% of issued shares, to Kurabo; price was not disclosed.

Target
TAUNS Laboratories
Buyer
Kurabo Industries

Trustar Capital Japan Fund III has signed a share transfer agreement to sell 16,400,000 shares, or 15.4% of issued shares, in TAUNS Laboratories to Kurabo Industries. The transfer is scheduled for November 30, 2026, and the value of the transaction was not disclosed. TAUNS and Kurabo have also agreed a capital and business alliance, and TAUNS will become an equity-method affiliate of Kurabo.

TAUNS, based in Izunokuni City, Shizuoka Prefecture, develops, manufactures and sells in vitro diagnostic medical devices and research reagents. Trustar Capital Japan Fund invested in TAUNS in July 2016 and will remain a shareholder after the transfer.

According to the parties, the two companies will combine technologies, R&D capabilities, manufacturing know-how, sales networks and human resources to create new products and services, strengthen production systems and expand sales. Kurabo has named Life Science and Technology as a core focus area in its medium-term plan, "Accelerate '27."

Background

Business
In vitro diagnostic medical devices, research reagents and other products, primarily for infectious diseases
Deal type
Exit
Headquarters
Izunokuni City, Shizuoka Prefecture

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.